Live Chat

CFD:er är komplexa instrument som innebär hög risk att du förlorar pengar snabbt på grund av hävstången. 74% av icke-professionella investerares konton förlorar pengar när de handlar med CFD:er hos den här leverantören. Du bör överväga om du förstår hur CFD:er fungerar och om du har råd att ta den höga risken att förlora dina pengar.

Close

Affär Gilead GILD

Gilead realtidsdiagram

Instrumentfundament

Weekly Search
Weekly
Daily
Datum Stäng Förändring Förändring (%) Öppna Hög Låg

Senaste nyheter

Frances Wang 2024 Dec 19, 16:00

Analyst revises Amazon stock forecast following major 'moonshot' initiative

Stocks
Frances Wang 2024 Dec 19, 16:00

Stock market today: 3 bullish stocks that J.P. Morgan Just Upgraded

Stocks
Frances Wang 2024 Dec 19, 16:00

Bitcoin news today: Jerome Powell Says Fed Won’t Hold Bitcoin

Cryptocurrencies
Frances Wang 2024 Dec 19, 16:00

Gold performance and prediction: how high could gold price go?

Commodities
UK GDP
Dyogenes Diniz 2024 Dec 19, 16:00

Week ahead: Last full week of 2024 in the Financial Markets

Forex Indices
Frances Wang 2024 Dec 18, 16:00

Stock market today: Nasdaq Hits Record Highs as Tesla Achieves New Peaks

Stocks
Frances Wang 2024 Dec 18, 16:00

Dow Jones tumbles 1,100 points: why did the stock market go down today?

Stocks
Frances Wang 2024 Dec 18, 16:00

Super Micro Shares Drop 8% Following Nasdaq 100 Removal

Stocks

Info

Spread

0.57

Spread (%)

0.6176 %

Hävstångseffekt

1:5

Köp till dagslåneränta

-0.0597 %

Sälj till dagslåneränta

-0.0292 %

Valuta

USD

Handelstider

Marknaderna är stängda

Måndag

14:31 - 20:59

Tisdag

14:31-17:59

Torsdag

14:31-20:59

Fredag

14:31-20:59

Analys och statistik

Öppna

---

Föregående stängning

---

52 veckors högsta/lägsta

--- – ---

Marknadsvärde

115367206912

Utelöpande aktier

1246269952

Rapportdatum (nästa)

2013-01-28

Utd-procent

2024-12-30

Datum efter utdelning

2024-12-13

Förväntad framtida årlig utdelningsprocent

3.08

Förväntad framtida årlig direktavkastning

0.0333

Vinst per aktie

0.09

Läs mer om detta instrument

Gilead Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Läs mer om detta instrument

Tillgång
Sälj
Köp
Förändring (%)
Relaterade instrument
Trustpilot
Live Chat